Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Pancreatic Neoplasms 15Stomach Neoplasms 14Rectal Neoplasms 10Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Locally Advanced Rectal Cancer 6Carcinoma, Non-Small-Cell Lung 6Liver Neoplasms 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Sarcoma 4Melanoma 4Lung Neoplasms 4Gastrointestinal Stromal Tumors 4Endometrial Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Neoplasms 2Mesothelioma 2

Interventions

pembrolizumab 25Nivolumab 20atezolizumab 8Magnetic Resonance Spectroscopy 7Ipilimumab 7Specimen Handling 5Paclitaxel 5Fluorodeoxyglucose F18 4Cyclophosphamide 4Carboplatin 4fludarabine 3durvalumab 3avelumab 3Interleukin-2 3Gemcitabine 3Docetaxel 3130-nm albumin-bound paclitaxel 3tislelizumab 2spartalizumab 2regorafenib 2epacadostat 2cabozantinib 2aldesleukin 2Taxes 2Pemetrexed 2FAPI-46 2Cisplatin 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × spartalizumab × Gastrointestinal × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡